Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients

Trial Profile

Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
    • 16 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov record.
    • 19 May 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top